1 Twycross R. Opioids. Dans : Wall P, Melzack R, editors. Textbook of pain. 4th ed. Edinburgh : Churchill Livingstone, 1999 ; 1187-215.
2 Daeninck PJ, Bruera E. Opioid use in cancer pain. Is a more liberal approach enhancing toxicity ? Acta Anaesthesiol Scand 1999 ; 43 : 924-38.
3 Galer B, Coyle N, Pasternak G, Portenoy R. Individual variability in the response to different opioids : Report of five cases. Pain 1992 ; 49 : 87-91.
4 MacDonald N, Der L, Allan S, Champion P. Opioid hyperexcitability : The application of alternate opioid therapy. Pain 1993 ; 53 : 353-5.
5 Sjogren P, Jonsson T, Jensen NH, Drenck NE, Staehelin Jensen T. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993 ; 55 : 93-7.
6 de Stoutz N, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995 ; 10 : 378-83.
7 Ashby M, Martin P, Jackson K. Opioid substitution to reduce adverse effects in cancer pain management. Med J Austr 1999 ; 170 : 68-71.
8 Reisine T, Pasternak G. Opioid analgesics and antagonists. Dans : Hardman J, Limbird L, Molinoff P, Ruddon R, Goodman Gilman A, editors. The pharmacological basis of therapeutics. 9th ed. New York : McGraw-Hill, 1996 ; 521-55.
9 Cox BM. Opioid receptor-G protein interactions : Acute and chronic effects of opioids. Dans : Herz A, editor. Opioids I. 1st ed. Berlin : Springer-
Verlag, 1993 ; 145-88.
10 Mogil J, Sternberg W, Marek P, et al. The genetics of pain and pain inhibition. Proc Natl Acad Sci 1996 ; 93 : 3048-55.
11 Ebert B, Thorkildsen C, Andersen S, Christrup L, Hjeds H. Opioid analgesics as noncompetitive N-methyl-D-aspartate antagonists. Biochem Pharmacol 1998 ; 56 : 553-9.
12 Mao J, Price D, Mayer D. Mechanisms of hyperalgesia and morphine tolerance : A current view of their possible interactions. Pain 1995 ; 62 : 259-74.
13 Davis A, Inturrisi C. d-Methadone blocks morphine tolerance and N-methyl--D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 1999 ; 289 : 1048-53.
14 Szeto H, Inturrisi C, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 1977 ; 86 : 738-41.
15 Kaiko R, Foley K, Grabinski P, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983 ; 13 : 180-5.
16 Smith M, Watt J, Cramond T. Morphine-3-glucuronide a potent antagonist of morphine analgesia. Life Sci 1990 ; 47 : 579-85.
17 Gong QL, Hedner J, Björkman R, Hedner T. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992 ; 48 : 249-55.
18 Faura C, Olaso MJ, García Cabanes C, Horga J. Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved ? Pain 1996 ; 65 : 25-30.
19 Bartlett S, Cramond T, Smith M. The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. Life Sci 1994 ; 54 : 687-94.
20 Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration : Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990 ; 47 : 12-9.
21 Osborne R, Joel S, Grebenik K, Trew D, Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 1993 ; 54 : 158-67.
22 Peterson GM, Randall CTC, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain : Relationship to renal function and route of administration. Eur J Clin Pharmacol 1990 ; 38 : 121-4.
23 Portenoy R, Foley K, Stulman J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain : Plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991 ; 47 : 13-9.
24 Hagen N, Foley K, Cerbone D, Portenoy R, Inturrisi C. Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manag 1991 ; 6 : 125-8.
25 Wright A, Nocente ML, Smith M. Hydromorphone-3-glucuronide : Biochemical synthesis and preliminary pharmacological evaluation. Life Sci 1998 ; 63 : 401-11.
26 Samuelsson H, Hedner T, Venn R, Michalkiewicz A. CSF and plasma concentrations of morphine and morphine glucuronides in cancer patients receiving epidural morphine. Pain 1993 ; 52 : 179-85.
27 Goucke C, Hackett L, Ilett K. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain. Pain 1994 ; 56 : 145-9.
28 Wolff T, Samuelsson H, Hedner T. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain 1995 ; 62 : 147-54.
29 Ivarsson M, Neil A. Differences in efficacies between morphine and methadone demonstrated in the guinea pig ileum : A possible explanation for previous observations on incomplete opioid cross-tolerance. Pharmacol Toxicol 1989 ; 65 : 368-71.
30 Sosnowski M, Yaksh T. Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. Anesthesiology 1990 ; 73 : 1141-7.
31 Duttaroy A, Yoburn B. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 1995 ; 82 : 1226-36.
32 Dirig D, Yaksh T. Differential right shifts in the dose-response curve for intrathecal morphine and sufentanil as a function of stimulus intensity. Pain 1995 ; 62 : 321-
8.
33 Saeki S, Yaksh T. Suppression of nociceptive responses by spinal mu opioid agonists : Effects of stimulus intensity and agonist efficacy. Anesth Analg 1993 ; 77 : 265-74.
